Severe neutropenia and prophylactic doses of rifabutin [19]

Lancet

Volumn 348, Issue 9041, 1996, Pages 1592-1593

  Tansey, M J ^a   Moe, J B ^a   Apseloff, G ^a   Foulds, G ^a   LaBoy Goral, L ^a   Vincent, J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CD4 ANTIGEN; CLARITHROMYCIN; MACROLIDE; RIFABUTIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; BONE MARROW TOXICITY; CLINICAL TRIAL; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LETTER; LEUKOCYTE COUNT; LEUKOPENIA; MYCOBACTERIUM AVIUM; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0029802304     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)66217-4     Document Type: Letter

References (5)

1. DV Havlir MP Dube FR Sattler Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both N Engl J Med 335 1996 392 398
2. M Brughera G Scampini AJ Newman S Castellino U Sammartini G Mazue Overview of toxicological data on rifabutin Exp Toxicol Pathol 47 1995 1 9
3. DE Griffith BA Brown WM Girard Wallace RJ Jr Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease Clin Infect Dis 21 1995 594 598
4. Horsburgh CR Jr Advances in the prevention and treatment of Mycobacterium avium disease N Engl J Med 336 1996 428 429
5. G Apseloff G Feulds L LaBoy-Goral E Kraut J Vincent Severe neutropenia caused by recommended prophylactic doses of rifabutin Lancet 348 1996 685